{"transactions":[{"id":734165,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2026-06-18T00:00:06.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":false,"shares":219,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":1313,"derivative":{"underlying":"Common Stock","underlying_shares":219},"source":{"system":"sec-edgar","filing":"0001104659-26-075298","document":"tm2618120-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926075298/tm2618120-1_4seq1.xml","form_type":"4"}},{"id":734164,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-06-18T00:00:06.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":true,"shares":219,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":69817,"source":{"system":"sec-edgar","filing":"0001104659-26-075298","document":"tm2618120-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926075298/tm2618120-1_4seq1.xml","form_type":"4"}},{"id":766004,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2026-05-22T23:00:13.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":false,"shares":49758,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On January 1, 2026, the Reporting Person was granted 199,032 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On January 1, 2026, the Reporting Person was granted 199,032 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":149274,"derivative":{"underlying":"Common Stock","underlying_shares":49758},"source":{"system":"sec-edgar","filing":"0001104659-26-065836","document":"tm2615413-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926065836/tm2615413-1_4seq1.xml","form_type":"4"}},{"id":766003,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-05-22T23:00:13.000Z","date":"2026-05-20","kind":"sale","planned":true,"acquired":false,"shares":19419,"price":1.087,"value":21108.453,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 3, 2026 solely to cover taxes due in connection with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $1.07 to $1.105. The Reporting Person undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":69598,"source":{"system":"sec-edgar","filing":"0001104659-26-065836","document":"tm2615413-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926065836/tm2615413-1_4seq1.xml","form_type":"4"}},{"id":766002,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-05-22T23:00:13.000Z","date":"2026-05-04","kind":"exercise","planned":true,"acquired":true,"shares":49758,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":89017,"source":{"system":"sec-edgar","filing":"0001104659-26-065836","document":"tm2615413-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926065836/tm2615413-1_4seq1.xml","form_type":"4"}},{"id":788530,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2026-05-07T23:01:33.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":false,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 18,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 18,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001104659-26-057367","document":"tm2613630-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926057367/tm2613630-4_4seq1.xml","form_type":"4"}},{"id":788529,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-05-07T23:01:33.000Z","date":"2026-05-01","kind":"exercise","planned":false,"acquired":true,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":39259,"source":{"system":"sec-edgar","filing":"0001104659-26-057367","document":"tm2613630-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926057367/tm2613630-4_4seq1.xml","form_type":"4"}},{"id":841672,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2026-03-17T00:05:59.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":false,"shares":219,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":1532,"derivative":{"underlying":"Common Stock","underlying_shares":219},"source":{"system":"sec-edgar","filing":"0001104659-26-028722","document":"tm268882-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926028722/tm268882-4_4seq1.xml","form_type":"4"}},{"id":841671,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2026-03-17T00:05:59.000Z","date":"2026-03-14","kind":"exercise","planned":false,"acquired":false,"shares":164,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":488,"derivative":{"underlying":"Common Stock","underlying_shares":164},"source":{"system":"sec-edgar","filing":"0001104659-26-028722","document":"tm268882-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926028722/tm268882-4_4seq1.xml","form_type":"4"}},{"id":841670,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-03-17T00:05:59.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":true,"shares":219,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":21259,"source":{"system":"sec-edgar","filing":"0001104659-26-028722","document":"tm268882-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926028722/tm268882-4_4seq1.xml","form_type":"4"}},{"id":841669,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-03-17T00:05:59.000Z","date":"2026-03-14","kind":"exercise","planned":false,"acquired":true,"shares":164,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":21040,"source":{"system":"sec-edgar","filing":"0001104659-26-028722","document":"tm268882-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926028722/tm268882-4_4seq1.xml","form_type":"4"}},{"id":951635,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2026-01-06T01:00:47.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":199032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On January 1, 2026, the Reporting Person was granted 199,032 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On January 1, 2026, the Reporting Person was granted 199,032 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the \"Vesting Commencement Date\"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":200783,"derivative":{"underlying":"Common Stock","underlying_shares":199032},"source":{"system":"sec-edgar","filing":"0001104659-26-000835","document":"tm261931-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465926000835/tm261931-2_4seq1.xml","form_type":"4"}},{"id":969520,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2025-12-16T01:02:47.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":false,"shares":219,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":1751,"derivative":{"underlying":"Common Stock","underlying_shares":219},"source":{"system":"sec-edgar","filing":"0001104659-25-121304","document":"tm2533410-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925121304/tm2533410-4_4seq1.xml","form_type":"4"}},{"id":969519,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2025-12-16T01:02:47.000Z","date":"2025-12-14","kind":"exercise","planned":false,"acquired":false,"shares":164,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":652,"derivative":{"underlying":"Common Stock","underlying_shares":164},"source":{"system":"sec-edgar","filing":"0001104659-25-121304","document":"tm2533410-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925121304/tm2533410-4_4seq1.xml","form_type":"4"}},{"id":969518,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2025-12-16T01:02:47.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":true,"shares":219,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":20876,"source":{"system":"sec-edgar","filing":"0001104659-25-121304","document":"tm2533410-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925121304/tm2533410-4_4seq1.xml","form_type":"4"}},{"id":969517,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2025-12-16T01:02:47.000Z","date":"2025-12-14","kind":"exercise","planned":false,"acquired":true,"shares":164,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":20657,"source":{"system":"sec-edgar","filing":"0001104659-25-121304","document":"tm2533410-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925121304/tm2533410-4_4seq1.xml","form_type":"4"}},{"id":1039387,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2025-09-16T23:05:59.000Z","date":"2025-09-15","kind":"exercise","planned":false,"acquired":false,"shares":219,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":1970,"derivative":{"underlying":"Common Stock","underlying_shares":219},"source":{"system":"sec-edgar","filing":"0001104659-25-090518","document":"tm2526247-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925090518/tm2526247-4_4seq1.xml","form_type":"4"}},{"id":1039386,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2025-09-16T23:05:59.000Z","date":"2025-09-14","kind":"exercise","planned":false,"acquired":false,"shares":163,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":816,"derivative":{"underlying":"Common Stock","underlying_shares":163},"source":{"system":"sec-edgar","filing":"0001104659-25-090518","document":"tm2526247-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925090518/tm2526247-4_4seq1.xml","form_type":"4"}},{"id":1039385,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2025-09-16T23:05:59.000Z","date":"2025-09-15","kind":"exercise","planned":false,"acquired":true,"shares":219,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":20493,"source":{"system":"sec-edgar","filing":"0001104659-25-090518","document":"tm2526247-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925090518/tm2526247-4_4seq1.xml","form_type":"4"}},{"id":1039384,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2025-09-16T23:05:59.000Z","date":"2025-09-14","kind":"exercise","planned":false,"acquired":true,"shares":163,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":20274,"source":{"system":"sec-edgar","filing":"0001104659-25-090518","document":"tm2526247-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925090518/tm2526247-4_4seq1.xml","form_type":"4"}},{"id":1074645,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2025-08-06T00:00:14.000Z","date":"2025-08-01","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 18,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 1, 2025 (the \"Grant Date\"), the Reporting Person was granted 18,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date."}],"balance_after":18000,"derivative":{"underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001104659-25-074369","document":"tm2522669-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925074369/tm2522669-1_4seq1.xml","form_type":"4"}},{"id":1083438,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2025-07-23T00:29:37.000Z","date":"2025-07-22","kind":"grant","planned":false,"acquired":true,"shares":15625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through July 22, 2025 (the \"PSUs\"). On July 22, 2025, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 15,625 PSUs had been satisfied and 15,625 shares of common stock became issuable to the Reporting Person on July 22, 2025."}],"balance_after":20111,"source":{"system":"sec-edgar","filing":"0001104659-25-069703","document":"tm2521458-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925069703/tm2521458-4_4seq1.xml","form_type":"4"}},{"id":1109837,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2025-06-16T23:01:03.000Z","date":"2025-06-15","kind":"exercise","planned":false,"acquired":false,"shares":219,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":2189,"derivative":{"underlying":"Common Stock","underlying_shares":219},"source":{"system":"sec-edgar","filing":"0001104659-25-059980","document":"tm2518140-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925059980/tm2518140-2_4seq1.xml","form_type":"4"}},{"id":1109836,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2025-06-16T23:01:03.000Z","date":"2025-06-14","kind":"exercise","planned":false,"acquired":false,"shares":163,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":979,"derivative":{"underlying":"Common Stock","underlying_shares":163},"source":{"system":"sec-edgar","filing":"0001104659-25-059980","document":"tm2518140-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925059980/tm2518140-2_4seq1.xml","form_type":"4"}},{"id":1109835,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2025-06-16T23:01:03.000Z","date":"2025-06-15","kind":"exercise","planned":false,"acquired":true,"shares":219,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":4486,"source":{"system":"sec-edgar","filing":"0001104659-25-059980","document":"tm2518140-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925059980/tm2518140-2_4seq1.xml","form_type":"4"}},{"id":1109834,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2025-06-16T23:01:03.000Z","date":"2025-06-14","kind":"exercise","planned":false,"acquired":true,"shares":163,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":4267,"source":{"system":"sec-edgar","filing":"0001104659-25-059980","document":"tm2518140-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925059980/tm2518140-2_4seq1.xml","form_type":"4"}},{"id":1186510,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-01T22:08:00.000Z","date":"2024-07-22","kind":"grant","planned":false,"acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount has been adjusted to reflect the reverse stock split effective on February 7, 2025 whereby every sixteen shares issued and outstanding prior to the split were combined and converted into one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Reporting Person was granted an option to purchase 6,250 shares of common stock, which vests as to 50% on each of the first and second anniversaries of the grant date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":6250,"derivative":{"exercise_price":1.2,"expiration_date":"2034-07-22","underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001104659-25-030686","document":"tm2511097-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925030686/tm2511097-6_4seq1.xml","form_type":"4"}},{"id":1203841,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2025-03-17T22:35:35.000Z","date":"2025-03-15","kind":"exercise","planned":false,"acquired":false,"shares":217,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":2408,"derivative":{"underlying":"Common Stock","underlying_shares":217},"source":{"system":"sec-edgar","filing":"0001104659-25-024531","document":"tm259558-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925024531/tm259558-1_4seq1.xml","form_type":"4"}},{"id":1203840,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2025-03-17T22:35:35.000Z","date":"2025-03-14","kind":"exercise","planned":false,"acquired":false,"shares":162,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":1142,"derivative":{"underlying":"Common Stock","underlying_shares":162},"source":{"system":"sec-edgar","filing":"0001104659-25-024531","document":"tm259558-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925024531/tm259558-1_4seq1.xml","form_type":"4"}},{"id":1203839,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2025-03-17T22:35:35.000Z","date":"2025-03-15","kind":"exercise","planned":false,"acquired":true,"shares":217,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":4104,"source":{"system":"sec-edgar","filing":"0001104659-25-024531","document":"tm259558-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925024531/tm259558-1_4seq1.xml","form_type":"4"}},{"id":1203838,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2025-03-17T22:35:35.000Z","date":"2025-03-14","kind":"exercise","planned":false,"acquired":true,"shares":162,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":3887,"source":{"system":"sec-edgar","filing":"0001104659-25-024531","document":"tm259558-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925024531/tm259558-1_4seq1.xml","form_type":"4"}},{"id":1305231,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-11T01:03:20.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":660000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 7, 2025, the Reporting Person was granted an option to purchase 660,000 shares of common stock, which vests in twelve equal monthly installments over a twelve-month period following the grant date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":660000,"derivative":{"exercise_price":0.4713,"expiration_date":"2035-01-07","underlying":"Common Stock","underlying_shares":660000},"source":{"system":"sec-edgar","filing":"0001104659-25-002693","document":"tm252892-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465925002693/tm252892-4_4seq1.xml","form_type":"4"}},{"id":1328872,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2024-12-17T23:08:34.000Z","date":"2024-12-15","kind":"exercise","planned":true,"acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On March 15, 2023, the Reporting Person was granted 56,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On March 15, 2023, the Reporting Person was granted 56,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":31500,"derivative":{"underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001104659-24-129462","document":"tm2431371-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924129462/tm2431371-4_4seq1.xml","form_type":"4"}},{"id":1328871,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2024-12-17T23:08:34.000Z","date":"2024-12-14","kind":"exercise","planned":true,"acquired":false,"shares":2610,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":13049,"derivative":{"underlying":"Common Stock","underlying_shares":2610},"source":{"system":"sec-edgar","filing":"0001104659-24-129462","document":"tm2431371-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924129462/tm2431371-4_4seq1.xml","form_type":"4"}},{"id":1328870,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-12-17T23:08:34.000Z","date":"2024-12-16","kind":"sale","planned":true,"acquired":false,"shares":2134,"price":0.3624,"value":773.3616,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The Reporting Person undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":59605,"source":{"system":"sec-edgar","filing":"0001104659-24-129462","document":"tm2431371-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924129462/tm2431371-4_4seq1.xml","form_type":"4"}},{"id":1328869,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-12-17T23:08:34.000Z","date":"2024-12-16","kind":"sale","planned":true,"acquired":false,"shares":983,"price":0.3641,"value":357.9103,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The Reporting Person undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":60920,"source":{"system":"sec-edgar","filing":"0001104659-24-129462","document":"tm2431371-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924129462/tm2431371-4_4seq1.xml","form_type":"4"}},{"id":1328868,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-12-17T23:08:34.000Z","date":"2024-12-15","kind":"exercise","planned":true,"acquired":true,"shares":3500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":61903,"source":{"system":"sec-edgar","filing":"0001104659-24-129462","document":"tm2431371-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924129462/tm2431371-4_4seq1.xml","form_type":"4"}},{"id":1328867,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-12-17T23:08:34.000Z","date":"2024-12-14","kind":"exercise","planned":true,"acquired":true,"shares":2610,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":58403,"source":{"system":"sec-edgar","filing":"0001104659-24-129462","document":"tm2431371-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924129462/tm2431371-4_4seq1.xml","form_type":"4"}},{"id":1405148,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2024-09-17T23:21:47.000Z","date":"2024-09-15","kind":"exercise","planned":true,"acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 15, 2023, the Reporting Person was granted 56,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 15, 2023, the Reporting Person was granted 56,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":35000,"derivative":{"underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001104659-24-100751","document":"tm2424255-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924100751/tm2424255-6_4seq1.xml","form_type":"4"}},{"id":1405147,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2024-09-17T23:21:47.000Z","date":"2024-09-14","kind":"exercise","planned":true,"acquired":false,"shares":2609,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":15657,"derivative":{"underlying":"Common Stock","underlying_shares":2609},"source":{"system":"sec-edgar","filing":"0001104659-24-100751","document":"tm2424255-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924100751/tm2424255-6_4seq1.xml","form_type":"4"}},{"id":1405146,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-09-17T23:21:47.000Z","date":"2024-09-16","kind":"sale","planned":true,"acquired":false,"shares":1150,"price":0.6905,"value":794.075,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023."}],"balance_after":51666,"source":{"system":"sec-edgar","filing":"0001104659-24-100751","document":"tm2424255-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924100751/tm2424255-6_4seq1.xml","form_type":"4"}},{"id":1405145,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-09-17T23:21:47.000Z","date":"2024-09-16","kind":"sale","planned":true,"acquired":false,"shares":832,"price":0.6885,"value":572.832,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023."}],"balance_after":52816,"source":{"system":"sec-edgar","filing":"0001104659-24-100751","document":"tm2424255-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924100751/tm2424255-6_4seq1.xml","form_type":"4"}},{"id":1405144,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-09-17T23:21:47.000Z","date":"2024-09-15","kind":"exercise","planned":true,"acquired":true,"shares":3500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":53648,"source":{"system":"sec-edgar","filing":"0001104659-24-100751","document":"tm2424255-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924100751/tm2424255-6_4seq1.xml","form_type":"4"}},{"id":1405143,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-09-17T23:21:47.000Z","date":"2024-09-14","kind":"exercise","planned":true,"acquired":true,"shares":2609,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":50148,"source":{"system":"sec-edgar","filing":"0001104659-24-100751","document":"tm2424255-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924100751/tm2424255-6_4seq1.xml","form_type":"4"}},{"id":1475422,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2024-06-19T01:24:43.000Z","date":"2024-06-15","kind":"exercise","planned":true,"acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On March 15, 2023, the Reporting Person was granted 56,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On March 15, 2023, the Reporting Person was granted 56,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":38500,"derivative":{"underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001104659-24-072999","document":"tm2417544-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924072999/tm2417544-1_4seq1.xml","form_type":"4"}},{"id":1475421,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2024-06-19T01:24:43.000Z","date":"2024-06-14","kind":"exercise","planned":true,"acquired":false,"shares":2609,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":18266,"derivative":{"underlying":"Common Stock","underlying_shares":2609},"source":{"system":"sec-edgar","filing":"0001104659-24-072999","document":"tm2417544-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924072999/tm2417544-1_4seq1.xml","form_type":"4"}},{"id":1475420,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-06-19T01:24:43.000Z","date":"2024-06-17","kind":"sale","planned":true,"acquired":false,"shares":2134,"price":1.2835,"value":2738.989,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in a weighted average price. The securities were sold in multiple transactions at a per share prices ranging from $1.275 to $1.295. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sole at each separate price within the range set forth in this footnote."}],"balance_after":47539,"source":{"system":"sec-edgar","filing":"0001104659-24-072999","document":"tm2417544-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924072999/tm2417544-1_4seq1.xml","form_type":"4"}},{"id":1475419,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-06-19T01:24:43.000Z","date":"2024-06-15","kind":"exercise","planned":true,"acquired":true,"shares":3500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":49673,"source":{"system":"sec-edgar","filing":"0001104659-24-072999","document":"tm2417544-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924072999/tm2417544-1_4seq1.xml","form_type":"4"}},{"id":1475418,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-06-19T01:24:43.000Z","date":"2024-06-14","kind":"exercise","planned":true,"acquired":true,"shares":2609,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":46173,"source":{"system":"sec-edgar","filing":"0001104659-24-072999","document":"tm2417544-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924072999/tm2417544-1_4seq1.xml","form_type":"4"}},{"id":1488547,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}},{"id":90201,"kind":"organization","name":"BioXcel Holdings, Inc.","position":2,"cik":"0001811154","reported_name":"BioXcel Holdings, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90202,"kind":"organization","name":"BioXcel LLC","position":3,"cik":"0001651990","reported_name":"BioXcel LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Call Options (obligation to sell)","published_at":"2024-06-06T20:35:48.000Z","date":"2024-06-04","kind":"sale","planned":false,"acquired":false,"shares":120,"ownership":{"direct":false,"nature":"By BioXcel LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The warrants underlying each call option will be exercisable for common interests in BioXcel LLC at an exercise price per common interest equal to $1,709.88."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"BioXcel LLC has agreed to redeem each common interest in BioXcel LLC acquired pursuant to the exercise of the warrant described in footnote 7 above in exchange for 149.22 shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). Vimal Mehta, Ph.D. is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC. By virtue of these relationships, Parent and Dr. Mehta may be deemed to be the beneficial owners of the securities held of record by BioXcel LLC. Each disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":120,"derivative":{"exercise_date":"2024-06-04","expiration_date":"2026-08-31","underlying":"Common Stock","underlying_shares":17906},"source":{"system":"sec-edgar","filing":"0001104659-24-069195","document":"tm2416676-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1811154/000110465924069195/tm2416676-1_4seq1.xml","form_type":"4"}},{"id":1488546,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}},{"id":90201,"kind":"organization","name":"BioXcel Holdings, Inc.","position":2,"cik":"0001811154","reported_name":"BioXcel Holdings, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90202,"kind":"organization","name":"BioXcel LLC","position":3,"cik":"0001651990","reported_name":"BioXcel LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-06T20:35:48.000Z","date":"2024-06-05","kind":"sale","planned":false,"acquired":false,"shares":126014,"price":1.5841,"value":199618.7774,"ownership":{"direct":false,"nature":"By BioXcel LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents sales of an amount of shares of Common Stock sufficient to cover certain tax liabilities incurred in connection with the transfers of Common Stock reported herein."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at a per share prices ranging from $1.55 to $1.635. The Reporting Persons undertake to provide upon request of the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). Vimal Mehta, Ph.D. is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC. By virtue of these relationships, Parent and Dr. Mehta may be deemed to be the beneficial owners of the securities held of record by BioXcel LLC. Each disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":7685501,"source":{"system":"sec-edgar","filing":"0001104659-24-069195","document":"tm2416676-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1811154/000110465924069195/tm2416676-1_4seq1.xml","form_type":"4"}},{"id":1488545,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}},{"id":90201,"kind":"organization","name":"BioXcel Holdings, Inc.","position":2,"cik":"0001811154","reported_name":"BioXcel Holdings, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90202,"kind":"organization","name":"BioXcel LLC","position":3,"cik":"0001651990","reported_name":"BioXcel LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-06T20:35:48.000Z","date":"2024-06-04","kind":"sale","planned":false,"acquired":false,"shares":126014,"price":1.6309,"value":205516.2326,"ownership":{"direct":false,"nature":"By BioXcel LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents sales of an amount of shares of Common Stock sufficient to cover certain tax liabilities incurred in connection with the transfers of Common Stock reported herein."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at a per share prices ranging from $1.605 to $1.68. The Reporting Persons undertake to provide upon request of the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). Vimal Mehta, Ph.D. is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC. By virtue of these relationships, Parent and Dr. Mehta may be deemed to be the beneficial owners of the securities held of record by BioXcel LLC. Each disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":7811515,"source":{"system":"sec-edgar","filing":"0001104659-24-069195","document":"tm2416676-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1811154/000110465924069195/tm2416676-1_4seq1.xml","form_type":"4"}},{"id":1488544,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}},{"id":90201,"kind":"organization","name":"BioXcel Holdings, Inc.","position":2,"cik":"0001811154","reported_name":"BioXcel Holdings, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90202,"kind":"organization","name":"BioXcel LLC","position":3,"cik":"0001651990","reported_name":"BioXcel LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-06T20:35:48.000Z","date":"2024-06-05","kind":"sale","planned":false,"acquired":false,"shares":283122,"ownership":{"direct":false,"nature":"By Holdings, Inc."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to certain agreements, BioXcel LLC transferred 566,245 shares of Common Stock to Parent (defined below) and 42,976 shares of Common Stock to certain of its other members, each in exchange for common interests in BioXcel LLC. Subsequently, Parent transferred 566,245 shares of Common Stock to certain of its stockholders in exchange for their interests in Parent."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). Vimal Mehta, Ph.D. is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC. By virtue of these relationships, Parent and Dr. Mehta may be deemed to be the beneficial owners of the securities held of record by BioXcel LLC. Each disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-24-069195","document":"tm2416676-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1811154/000110465924069195/tm2416676-1_4seq1.xml","form_type":"4"}},{"id":1488543,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}},{"id":90201,"kind":"organization","name":"BioXcel Holdings, Inc.","position":2,"cik":"0001811154","reported_name":"BioXcel Holdings, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90202,"kind":"organization","name":"BioXcel LLC","position":3,"cik":"0001651990","reported_name":"BioXcel LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-06T20:35:48.000Z","date":"2024-06-04","kind":"sale","planned":false,"acquired":false,"shares":283123,"ownership":{"direct":false,"nature":"By Holdings, Inc."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to certain agreements, BioXcel LLC transferred 566,245 shares of Common Stock to Parent (defined below) and 42,976 shares of Common Stock to certain of its other members, each in exchange for common interests in BioXcel LLC. Subsequently, Parent transferred 566,245 shares of Common Stock to certain of its stockholders in exchange for their interests in Parent."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects securities acquired pursuant to a transaction exempt from reporting under Rule 16a-13."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). Vimal Mehta, Ph.D. is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC. By virtue of these relationships, Parent and Dr. Mehta may be deemed to be the beneficial owners of the securities held of record by BioXcel LLC. Each disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":283122,"source":{"system":"sec-edgar","filing":"0001104659-24-069195","document":"tm2416676-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811154/000110465924069195/tm2416676-1_4seq1.xml","form_type":"4"}},{"id":1488542,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}},{"id":90201,"kind":"organization","name":"BioXcel Holdings, Inc.","position":2,"cik":"0001811154","reported_name":"BioXcel Holdings, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":90202,"kind":"organization","name":"BioXcel LLC","position":3,"cik":"0001651990","reported_name":"BioXcel LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-06T20:35:48.000Z","date":"2024-06-04","kind":"sale","planned":false,"acquired":false,"shares":609221,"ownership":{"direct":false,"nature":"By BioXcel LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to certain agreements, BioXcel LLC transferred 566,245 shares of Common Stock to Parent (defined below) and 42,976 shares of Common Stock to certain of its other members, each in exchange for common interests in BioXcel LLC. Subsequently, Parent transferred 566,245 shares of Common Stock to certain of its stockholders in exchange for their interests in Parent."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). Vimal Mehta, Ph.D. is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC. By virtue of these relationships, Parent and Dr. Mehta may be deemed to be the beneficial owners of the securities held of record by BioXcel LLC. Each disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":7937529,"source":{"system":"sec-edgar","filing":"0001104659-24-069195","document":"tm2416676-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811154/000110465924069195/tm2416676-1_4seq1.xml","form_type":"4"}},{"id":1545734,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2024-04-08T23:32:27.000Z","date":"2024-03-15","kind":"exercise","planned":true,"acquired":false,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On March 15, 2023, the Reporting Person was granted 56,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On March 15, 2023, the Reporting Person was granted 56,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":42000,"derivative":{"underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001104659-24-044861","document":"tm2411220-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924044861/tm2411220-5_4seq1.xml","form_type":"4"}},{"id":1545733,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2024-04-08T23:32:27.000Z","date":"2024-03-14","kind":"exercise","planned":true,"acquired":false,"shares":2610,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":20875,"derivative":{"underlying":"Common Stock","underlying_shares":2610},"source":{"system":"sec-edgar","filing":"0001104659-24-044861","document":"tm2411220-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924044861/tm2411220-5_4seq1.xml","form_type":"4"}},{"id":1545732,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-04-08T23:32:27.000Z","date":"2024-04-04","kind":"sale","planned":true,"acquired":false,"shares":4439,"price":2.6247,"value":11651.0433,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in a weighted average price. The securities were sold in multiple transactions at a per share prices ranging from $2.62 to $2.65. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sole at each separate price within the range set forth in this footnote."}],"balance_after":43564,"source":{"system":"sec-edgar","filing":"0001104659-24-044861","document":"tm2411220-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924044861/tm2411220-5_4seq1.xml","form_type":"4"}},{"id":1545731,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-04-08T23:32:27.000Z","date":"2024-04-04","kind":"sale","planned":true,"acquired":false,"shares":829,"price":2.62,"value":2171.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2023."}],"balance_after":48003,"source":{"system":"sec-edgar","filing":"0001104659-24-044861","document":"tm2411220-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924044861/tm2411220-5_4seq1.xml","form_type":"4"}},{"id":1545730,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-04-08T23:32:27.000Z","date":"2024-03-15","kind":"exercise","planned":true,"acquired":true,"shares":14000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":48832,"source":{"system":"sec-edgar","filing":"0001104659-24-044861","document":"tm2411220-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924044861/tm2411220-5_4seq1.xml","form_type":"4"}},{"id":1545729,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2024-04-08T23:32:27.000Z","date":"2024-03-14","kind":"exercise","planned":true,"acquired":true,"shares":2610,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":34832,"source":{"system":"sec-edgar","filing":"0001104659-24-044861","document":"tm2411220-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465924044861/tm2411220-5_4seq1.xml","form_type":"4"}},{"id":1707348,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2023-12-18T21:55:50.000Z","date":"2023-12-14","kind":"exercise","planned":false,"acquired":false,"shares":2609,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":23485,"derivative":{"underlying":"Common Stock","underlying_shares":2609},"source":{"system":"sec-edgar","filing":"0001104659-23-126924","document":"tm2333119-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923126924/tm2333119-4_4seq1.xml","form_type":"4"}},{"id":1707347,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-12-18T21:55:50.000Z","date":"2023-12-14","kind":"exercise","planned":false,"acquired":true,"shares":2609,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":32222,"source":{"system":"sec-edgar","filing":"0001104659-23-126924","document":"tm2333119-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923126924/tm2333119-4_4seq1.xml","form_type":"4"}},{"id":1778961,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2023-09-18T20:47:09.000Z","date":"2023-09-14","kind":"exercise","planned":false,"acquired":false,"shares":2610,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":26094,"derivative":{"underlying":"Common Stock","underlying_shares":2610},"source":{"system":"sec-edgar","filing":"0001104659-23-101635","document":"tm2326350d1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923101635/tm2326350d1_4seq1.xml","form_type":"4"}},{"id":1778960,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-09-18T20:47:09.000Z","date":"2023-09-14","kind":"exercise","planned":false,"acquired":true,"shares":2610,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents adjustment in number of shares to correct an inadvertent error in the number of shares directly owned following the reported transaction in the Form 4 filed on May 24, 2023 and Form 4s filed thereafter."}],"balance_after":29613,"source":{"system":"sec-edgar","filing":"0001104659-23-101635","document":"tm2326350d1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923101635/tm2326350d1_4seq1.xml","form_type":"4"}},{"id":1852415,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T22:40:04.000Z","date":"2023-06-16","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option is fully vested and exercisable."}],"balance_after":294000,"derivative":{"exercise_price":0.41,"expiration_date":"2027-08-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-23-072396","document":"tm2319006-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923072396/tm2319006-2_4seq1.xml","form_type":"4"}},{"id":1852414,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T22:40:04.000Z","date":"2023-06-15","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option is fully vested and exercisable."}],"balance_after":324000,"derivative":{"exercise_price":0.41,"expiration_date":"2027-08-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-23-072396","document":"tm2319006-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923072396/tm2319006-2_4seq1.xml","form_type":"4"}},{"id":1852413,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2023-06-16T22:40:04.000Z","date":"2023-06-14","kind":"exercise","planned":true,"acquired":false,"shares":2609,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":28704,"derivative":{"underlying":"Common Stock","underlying_shares":2609},"source":{"system":"sec-edgar","filing":"0001104659-23-072396","document":"tm2319006-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923072396/tm2319006-2_4seq1.xml","form_type":"4"}},{"id":1852412,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-06-16T22:40:04.000Z","date":"2023-06-16","kind":"sale","planned":true,"acquired":false,"shares":747,"price":21.89,"value":16351.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022."}],"balance_after":39903,"source":{"system":"sec-edgar","filing":"0001104659-23-072396","document":"tm2319006-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923072396/tm2319006-2_4seq1.xml","form_type":"4"}},{"id":1852411,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-06-16T22:40:04.000Z","date":"2023-06-16","kind":"sale","planned":true,"acquired":false,"shares":4266,"price":20.9,"value":89159.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.59 to $21.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":40650,"source":{"system":"sec-edgar","filing":"0001104659-23-072396","document":"tm2319006-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923072396/tm2319006-2_4seq1.xml","form_type":"4"}},{"id":1852410,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-06-16T22:40:04.000Z","date":"2023-06-16","kind":"sale","planned":true,"acquired":false,"shares":24987,"price":20.01,"value":499989.87,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.57 to $20.42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":44916,"source":{"system":"sec-edgar","filing":"0001104659-23-072396","document":"tm2319006-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923072396/tm2319006-2_4seq1.xml","form_type":"4"}},{"id":1852409,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-06-16T22:40:04.000Z","date":"2023-06-16","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":0.41,"value":12300.0,"ownership":{"direct":true},"balance_after":69903,"source":{"system":"sec-edgar","filing":"0001104659-23-072396","document":"tm2319006-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923072396/tm2319006-2_4seq1.xml","form_type":"4"}},{"id":1852408,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-06-16T22:40:04.000Z","date":"2023-06-15","kind":"sale","planned":true,"acquired":false,"shares":8012,"price":21.9,"value":175462.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.83 to $22.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":39903,"source":{"system":"sec-edgar","filing":"0001104659-23-072396","document":"tm2319006-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923072396/tm2319006-2_4seq1.xml","form_type":"4"}},{"id":1852407,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-06-16T22:40:04.000Z","date":"2023-06-15","kind":"sale","planned":true,"acquired":false,"shares":21988,"price":21.41,"value":470763.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.83 to $21.825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":47915,"source":{"system":"sec-edgar","filing":"0001104659-23-072396","document":"tm2319006-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923072396/tm2319006-2_4seq1.xml","form_type":"4"}},{"id":1852406,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-06-16T22:40:04.000Z","date":"2023-06-15","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":0.41,"value":12300.0,"ownership":{"direct":true},"balance_after":69903,"source":{"system":"sec-edgar","filing":"0001104659-23-072396","document":"tm2319006-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923072396/tm2319006-2_4seq1.xml","form_type":"4"}},{"id":1852405,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-06-16T22:40:04.000Z","date":"2023-06-14","kind":"exercise","planned":true,"acquired":true,"shares":2609,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":39903,"source":{"system":"sec-edgar","filing":"0001104659-23-072396","document":"tm2319006-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923072396/tm2319006-2_4seq1.xml","form_type":"4"}},{"id":1879822,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-05-24T20:37:44.000Z","date":"2023-05-22","kind":"sale","planned":true,"acquired":false,"shares":6500,"price":25.7909,"value":167640.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.45 to $26.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":37294,"source":{"system":"sec-edgar","filing":"0001104659-23-064163","document":"tm2316022-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923064163/tm2316022-4_4seq1.xml","form_type":"4"}},{"id":1891605,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2023-05-17T00:33:28.000Z","date":"2023-05-14","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On May 14, 2022, the Reporting Person was granted 15,000 RSUs that vested and settled on May 14, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On May 14, 2022, the Reporting Person was granted 15,000 RSUs that vested and settled on May 14, 2023."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-23-061539","document":"tm2316022-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923061539/tm2316022-3_4seq1.xml","form_type":"4"}},{"id":1891604,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-05-17T00:33:28.000Z","date":"2023-05-14","kind":"exercise","planned":false,"acquired":true,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":30894,"source":{"system":"sec-edgar","filing":"0001104659-23-061539","document":"tm2316022-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923061539/tm2316022-3_4seq1.xml","form_type":"4"}},{"id":1941755,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-22T23:30:34.000Z","date":"2023-03-21","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option is fully vested and exercisable."}],"balance_after":354000,"derivative":{"exercise_price":0.41,"expiration_date":"2027-08-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-23-035711","document":"tm239796-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923035711/tm239796-7_4seq1.xml","form_type":"4"}},{"id":1941754,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-22T23:30:34.000Z","date":"2023-03-20","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option is fully vested and exercisable."}],"balance_after":384000,"derivative":{"exercise_price":0.41,"expiration_date":"2027-08-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-23-035711","document":"tm239796-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923035711/tm239796-7_4seq1.xml","form_type":"4"}},{"id":1941753,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-03-22T23:30:34.000Z","date":"2023-03-21","kind":"sale","planned":false,"acquired":false,"shares":900,"price":20.15,"value":18135.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.08 to $20.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":15894,"source":{"system":"sec-edgar","filing":"0001104659-23-035711","document":"tm239796-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923035711/tm239796-7_4seq1.xml","form_type":"4"}},{"id":1941752,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-03-22T23:30:34.000Z","date":"2023-03-21","kind":"sale","planned":false,"acquired":false,"shares":29100,"price":19.7,"value":573270.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.06 to $20.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":16794,"source":{"system":"sec-edgar","filing":"0001104659-23-035711","document":"tm239796-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923035711/tm239796-7_4seq1.xml","form_type":"4"}},{"id":1941751,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-03-22T23:30:34.000Z","date":"2023-03-21","kind":"exercise","planned":false,"acquired":true,"shares":30000,"price":0.41,"value":12300.0,"ownership":{"direct":true},"balance_after":45894,"source":{"system":"sec-edgar","filing":"0001104659-23-035711","document":"tm239796-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923035711/tm239796-7_4seq1.xml","form_type":"4"}},{"id":1941750,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-03-22T23:30:34.000Z","date":"2023-03-20","kind":"sale","planned":false,"acquired":false,"shares":604,"price":18.88,"value":11403.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.81 to $19.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":15894,"source":{"system":"sec-edgar","filing":"0001104659-23-035711","document":"tm239796-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923035711/tm239796-7_4seq1.xml","form_type":"4"}},{"id":1941749,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-03-22T23:30:34.000Z","date":"2023-03-20","kind":"sale","planned":false,"acquired":false,"shares":3896,"price":18.22,"value":70985.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.79 to $18.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":16498,"source":{"system":"sec-edgar","filing":"0001104659-23-035711","document":"tm239796-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923035711/tm239796-7_4seq1.xml","form_type":"4"}},{"id":1941748,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-03-22T23:30:34.000Z","date":"2023-03-20","kind":"sale","planned":false,"acquired":false,"shares":5333,"price":18.86,"value":100580.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.75 to $19.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":20394,"source":{"system":"sec-edgar","filing":"0001104659-23-035711","document":"tm239796-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923035711/tm239796-7_4seq1.xml","form_type":"4"}},{"id":1941747,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-03-22T23:30:34.000Z","date":"2023-03-20","kind":"sale","planned":false,"acquired":false,"shares":24667,"price":18.2,"value":448939.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.75 to $18.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":25727,"source":{"system":"sec-edgar","filing":"0001104659-23-035711","document":"tm239796-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923035711/tm239796-7_4seq1.xml","form_type":"4"}},{"id":1941746,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-03-22T23:30:34.000Z","date":"2023-03-20","kind":"exercise","planned":false,"acquired":true,"shares":30000,"price":0.41,"value":12300.0,"ownership":{"direct":true},"balance_after":50394,"source":{"system":"sec-edgar","filing":"0001104659-23-035711","document":"tm239796-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923035711/tm239796-7_4seq1.xml","form_type":"4"}},{"id":1950108,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-16T22:00:30.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":168000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of March 15, 2023 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":168000,"derivative":{"exercise_price":19.6,"expiration_date":"2033-03-15","underlying":"Common Stock","underlying_shares":168000},"source":{"system":"sec-edgar","filing":"0001104659-23-033403","document":"tm239796-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923033403/tm239796-4_4seq1.xml","form_type":"4"}},{"id":1950107,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2023-03-16T22:00:30.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs will vest and settle as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of Restricted Stock Units at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":56000,"derivative":{"underlying":"Common Stock","underlying_shares":56000},"source":{"system":"sec-edgar","filing":"0001104659-23-033403","document":"tm239796-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923033403/tm239796-4_4seq1.xml","form_type":"4"}},{"id":1950106,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2023-03-16T22:00:30.000Z","date":"2023-03-14","kind":"exercise","acquired":false,"shares":10437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates."}],"balance_after":31313,"derivative":{"underlying":"Common Stock","underlying_shares":10437},"source":{"system":"sec-edgar","filing":"0001104659-23-033403","document":"tm239796-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923033403/tm239796-4_4seq1.xml","form_type":"4"}},{"id":1950105,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-03-16T22:00:30.000Z","date":"2023-03-14","kind":"exercise","acquired":true,"shares":10437,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":20394,"source":{"system":"sec-edgar","filing":"0001104659-23-033403","document":"tm239796-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923033403/tm239796-4_4seq1.xml","form_type":"4"}},{"id":2016574,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2023-02-14T21:41:09.000Z","date":"2022-11-15","kind":"gift","acquired":false,"shares":145549,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent representing an approximate 1.7% economic interest in the shares of Issuer that are held of record by BioXcel LLC. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent representing an approximate 1.7% economic interest in the shares of Issuer that are held of record by BioXcel LLC. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":8546750,"source":{"system":"sec-edgar","filing":"0001104659-23-021767","document":"tm236671-1_5seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465923021767/tm236671-1_5seq1.xml","form_type":"5"}},{"id":2081760,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-20T01:00:31.000Z","date":"2022-12-16","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option is fully vested and exercisable."}],"balance_after":414000,"derivative":{"exercise_price":0.41,"expiration_date":"2027-08-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-22-128367","document":"tm2233011-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465922128367/tm2233011-1_4seq1.xml","form_type":"4"}},{"id":2081759,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-12-20T01:00:31.000Z","date":"2022-12-15","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option is fully vested and exercisable."}],"balance_after":444000,"derivative":{"exercise_price":0.41,"expiration_date":"2027-08-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-22-128367","document":"tm2233011-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465922128367/tm2233011-1_4seq1.xml","form_type":"4"}},{"id":2081758,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2022-12-20T01:00:31.000Z","date":"2022-12-16","kind":"sale","acquired":false,"shares":9887,"price":19.92,"value":196949.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.58 to $20.16, inclusive."}],"balance_after":9957,"source":{"system":"sec-edgar","filing":"0001104659-22-128367","document":"tm2233011-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465922128367/tm2233011-1_4seq1.xml","form_type":"4"}},{"id":2081757,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2022-12-20T01:00:31.000Z","date":"2022-12-16","kind":"sale","acquired":false,"shares":20113,"price":19.21,"value":386370.73,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.57 to $19.54, inclusive."}],"balance_after":19844,"source":{"system":"sec-edgar","filing":"0001104659-22-128367","document":"tm2233011-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465922128367/tm2233011-1_4seq1.xml","form_type":"4"}},{"id":2081756,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2022-12-20T01:00:31.000Z","date":"2022-12-16","kind":"exercise","acquired":true,"shares":30000,"price":0.41,"value":12300.0,"ownership":{"direct":true},"balance_after":39957,"source":{"system":"sec-edgar","filing":"0001104659-22-128367","document":"tm2233011-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465922128367/tm2233011-1_4seq1.xml","form_type":"4"}},{"id":2081755,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":37271,"kind":"person","name":"Mehta Vimal","position":1,"cik":"0001733369","reported_name":"Mehta Vimal","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2022-12-20T01:00:31.000Z","date":"2022-12-15","kind":"sale","acquired":false,"shares":7206,"price":20.19,"value":145489.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.13 to $20.29, inclusive."}],"balance_after":9957,"source":{"system":"sec-edgar","filing":"0001104659-22-128367","document":"tm2233011-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1733369/000110465922128367/tm2233011-1_4seq1.xml","form_type":"4"}}],"next_cursor":"2022-12-20T01:00:31.000000Z,2081755"}